{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/prescribing-information/ciprofloxacin/","result":{"pageContext":{"chapter":{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin","depth":2,"htmlHeader":"<!-- begin field be4a9199-ef88-4935-93a6-4383c0d28b53 --><h2>Ciprofloxacin</h2><!-- end field be4a9199-ef88-4935-93a6-4383c0d28b53 -->","summary":"","htmlStringContent":"<!-- begin item 0616734e-8015-455f-a2e9-33b781384e79 --><!-- end item 0616734e-8015-455f-a2e9-33b781384e79 -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"36887a29-69c8-5057-92ee-0846d71641b0","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4432850f-2de1-4280-844f-7a986b35838c --><h3>Contraindications and cautions</h3><!-- end field 4432850f-2de1-4280-844f-7a986b35838c -->","summary":"","htmlStringContent":"<!-- begin item 431a825c-16f2-4bcb-9596-062160bfce99 --><!-- begin field bbb4d5c0-198d-4335-99f0-8219da5e2431 --><ul><li><strong>Do not prescribe ciprofloxacin to people:</strong><ul><li>With a history of tendon disorders related to quinolone use.</li><li>Who have previously had serious adverse reactions with a quinolone or fluoroquinolone antibiotic.</li><li>Taking a corticosteroid — coadministration could exacerbate fluoroquinolone-induced tendonitis and tendon rupture.</li></ul></li><li><strong>Prescribe ciprofloxacin with caution to people with:</strong><ul><li>Positive family history of aneurysm disease or congenital heart valve disease.</li><li>Pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing for:<ul><li>Both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet's disease, hypertension, rheumatoid arthritis) <em>or additionally</em></li><li>Aortic aneurysm and dissection (such as vascular disorders including Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sjögren's syndrome) <em>or additionally</em></li><li>Heart valve regurgitation/incompetence (such as infective endocarditis).</li></ul></li><li>Epilepsy, or conditions that predispose to seizures, and in people taking other medication that may predispose to seizures, as quinolones can lower the seizure threshold.<ul><li>Quinolones may induce convulsions in patients with or without a history of convulsions, and taking NSAIDs at the same time may also induce them.</li></ul></li><li>Diabetes mellitus — may affect blood glucose. Blood glucose should be monitored closely.</li><li>Glucose-6-phosphate dehydrogenase deficiency —haemolytic reactions have been reported.</li><li>A history of tendonitis — quinolones can very rarely cause tendon damage, and the risk of tendon rupture is increased by co-administration of corticosteroid.</li><li>Conditions which predispose to QT interval prolongation:<ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (for example Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (for example hypokalaemia, or hypomagnesaemia).</li><li>Cardiac disease (for example, heart failure, myocardial infarction, or bradycardia).</li><li>Electrolyte disturbances.</li></ul></li><li>History of a psychotic disorder — there have been reports of suicidal thoughts or self-endangering behaviour after use quinolones. </li><li>Myasthenia gravis — symptoms can be exacerbated.</li></ul></li><li>Also prescribe with caution in people aged over 60 years, people with renal impairment or solid-organ transplants, as they are at a higher risk of tendon injury.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">MHRA, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2020</a>]</p><!-- end field bbb4d5c0-198d-4335-99f0-8219da5e2431 --><!-- end item 431a825c-16f2-4bcb-9596-062160bfce99 -->","subChapters":[]},{"id":"78acb93d-7864-5c97-baf3-dda0e54fe5c3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 678c41a4-7301-4fbe-a625-fd10acfbea79 --><h3>Adverse effects </h3><!-- end field 678c41a4-7301-4fbe-a625-fd10acfbea79 -->","summary":"","htmlStringContent":"<!-- begin item 4a20ac66-f3a1-45f5-a61c-960d287fee98 --><!-- begin field e61a09d3-0663-437d-a7f1-9992757e9b98 --><ul><li><strong>Gastrointestinal </strong>— diarrhoea, nausea (common), vomiting, dyspepsia, flatulence, gastrointestinal and abdominal pains (uncommon).<ul><li><strong>Rarely</strong>: pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>).</li></ul></li><li><strong>Musculoskeletal </strong>— pain, arthralgia (uncommon).<ul><li><strong>Rarely:</strong> myalgia, arthritis.</li><li><strong>Very rarely</strong>: muscle weakness, tendonitis, tendon damage — this may occur within 48 hours of starting treatment, or months after stopping. Risk of tendon rupture is increased by co-administration of corticosteroids and in people aged over 60 years. If tendonitis is suspected, ciprofloxacin should be discontinued immediately.</li></ul></li><li><strong>Nervous system</strong> — headache, dizziness, sleep disorders, taste disorders (uncommon).<ul><li><strong>Rarely</strong>: tremor, vertigo, lowering of the seizure threshold – this may trigger seizures. </li></ul></li><li><strong>Psychiatric</strong> — hyperactivity, agitation (uncommon).<ul><li><strong>Rarely</strong>: confusion, anxiety, depression, hallucinations.</li></ul></li><li><strong>Skin</strong> — rash, pruritus, urticaria.<ul><li><strong>Rarely: </strong>Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis anaphylaxis, drug rash with eosinophilia, systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP).</li></ul></li><li><strong>Cardiovascular system</strong> — there is an increased risk of aortic aneurysm and dissection with fluoroquinolones, particularly in the older population. Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in people with positive family history of aneurysm disease, or in people diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (for example, Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet’s disease, hypertension, known atherosclerosis).</li><li><strong>Other adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Hepatic impairment, hepatitis.</li><li>Renal impairment.</li><li>Tachycardia.</li><li>Tinnitus.</li><li>Visual disturbances.</li></ul></li><li><strong>NOTE: </strong>fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. People should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendonitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">MHRA, 2019</a>]</p><!-- end field e61a09d3-0663-437d-a7f1-9992757e9b98 --><!-- end item 4a20ac66-f3a1-45f5-a61c-960d287fee98 -->","subChapters":[]},{"id":"c60a0384-b832-53bc-baac-f2e44768bb58","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 59a2039d-145b-4da3-a7bf-a75a00d12c9d --><h3>Drug interactions </h3><!-- end field 59a2039d-145b-4da3-a7bf-a75a00d12c9d -->","summary":"","htmlStringContent":"<!-- begin item d314dcb8-2cbd-432e-a83e-a75a00d12cc3 --><!-- begin field 8d747c0a-1725-4146-9dd4-a75a00d12c9d --><ul><li><strong>Antacids (containing aluminium, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of ciprofloxacin if taken concurrently.<ul><li>Ciprofloxacin should be taken at least 2 hours before these preparations, and not less than 4 to 6 hours after them.</li></ul></li><li><strong>Ciclosporin</strong> — increased concentrations and nephrotoxicity might occur in a small number of patients.</li><li><strong>Corticosteroids</strong> — the risk of tendonitis and tendon rupture is increased in people taking a fluoroquinolone and a corticosteroid. The MHRA advises that concurrent should be avoided. </li><li><strong>Domperidone</strong> — the manufacturer advises that concurrent use with ciprofloxacin should be avoided as it may lead to QT interval prolongation.</li><li><strong>Ergometrine </strong>— levels may be increased, leading to ergotism. Concurrent use is contraindicated. </li><li><strong>Mizolastine</strong> — the manufacturer advises that concurrent use should be avoided. Mizolastine has a weak potential to cause QT interval prolongation in some people and this may be additive to the effects of ciprofloxacin.</li><li><strong>Methotrexate</strong> — plasma levels of methotrexate may be increased. The manufacturer recommends that concurrent use is avoided.<ul><li>If concurrent use is necessary, monitor methotrexate levels.</li></ul></li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— possible increased risk of seizures when quinolones are given with NSAIDs. Avoid concurrent use in people with epilepsy or people predisposed to seizures, or monitor them very closely.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of ciprofloxacin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Phenytoin</strong> — concurrent administration of ciprofloxacin can cause an increase or decrease in serum phenytoin levels. Monitor phenytoin levels.</li><li><strong>Strontium ranelate </strong>— the absorption of quinolones is reduced by strontium ranelate so they should not be given together.</li><li><strong>Theophylline </strong>— ciprofloxacin increases the plasma concentration of theophylline, leading to possible increased risk of convulsions. Monitor theophylline concentration closely.</li><li><strong>Tizanidine </strong>— ciprofloxacin increases the plasma concentration of tizanidine (increased risk of toxicity). Avoid conccurrent use.</li><li><strong>Warfarin </strong>— rarely, ciprofloxacin may enhance the anticoagulant effect, increasing the risk of bleeding. Monitor the international normalised ratio (INR) within 3 to 5 days of starting ciprofloxacin, frequently during and shortly after administration.</li><li><strong>Zolmitriptan </strong>— quinolones increase the plasma concentration of zolmitriptan by inhibiting its metabolism. Manufacturer recommends a maximum dose of 5 mg in 24 hours in people taking a quinolone.</li><li><strong>Drugs that prolong the QT interval </strong>(such as Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics) — very rare cases of QT interval prolongation have been reported in people taking quinolones and they should therefore be prescribed with caution alongside drugs known to prolong the QT interval.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">MHRA, 2019</a>]  </p><!-- end field 8d747c0a-1725-4146-9dd4-a75a00d12c9d --><!-- end item d314dcb8-2cbd-432e-a83e-a75a00d12cc3 -->","subChapters":[]},{"id":"9c945942-d531-54b9-9d78-e54486a0529d","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field a36177b0-98b0-4b6a-bd8e-a75a00d13a0a --><h3>Pregnancy and breastfeeding</h3><!-- end field a36177b0-98b0-4b6a-bd8e-a75a00d13a0a -->","summary":"","htmlStringContent":"<!-- begin item 4f45698f-7abc-488d-ad5a-a75a00d13a0c --><!-- begin field 1978dfc7-c690-4e93-b8a0-a75a00d13a0a --><h4>Pregnancy</h4><ul><li>Ciprofloxacin should be avoided in women who are pregnant.</li></ul><h4>Breastfeeding</h4><ul><li>Ciprofloxacin is excreted in breastmilk in quantities too small to be harmful, however the manufacturer advises that it should be avoided due to the risk of articular damage.<ul><li>However, studies indicate there is little risk, and quinolones are generally accepted for use during breastfeeding.</li><li>Avoiding breastfeeding for 3 to 4 hours after a dose should decrease the exposure of the infant to ciprofloxacin in breastmilk.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">LactMed, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 1978dfc7-c690-4e93-b8a0-a75a00d13a0a --><!-- end item 4f45698f-7abc-488d-ad5a-a75a00d13a0c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}